CK Life Sciences International (Holdings), Inc. (HK:0775)
:0775
Top Page
CK Life Sciences International (Holdings), Inc.
(0775)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$1.00
▲(20.48% Upside)
Action:ReiteratedDate:11/15/25
The overall stock score of 44 reflects significant concerns in financial performance, driven by a net loss, high debt levels, and declining cash flow, which pose risks to stability in the biotech sector. Valuation challenges with a negative P/E ratio further weigh on the score, while technical indicators suggest neutral market sentiment with no strong directional momentum.
Positive Factors
Revenue Growth
Consistent revenue growth indicates a stable demand for the company's products and suggests potential for future expansion in its markets.
Negative Factors
High Leverage
Increased leverage can elevate financial risk and limit the company's ability to invest in growth opportunities, affecting long-term stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates a stable demand for the company's products and suggests potential for future expansion in its markets.
Read all positive factors
CK Life Sciences International (Holdings), Inc. (0775) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$7.21B
Dividend YieldN/A
Average Volume (3M)7.56M
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth2.10%
EPS Growth-1350.00%
CountryHK
Employees2,033
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding9,611,072,000
10 Day Avg. Volume13,068,694
30 Day Avg. Volume7,559,299
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.12
Price to Sales (P/S)0.71
P/FCF Ratio25.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model
Company Description
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, markets, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and mark...
How the Company Makes Money
CK Life Sciences generates revenue through several key streams, primarily from the sale of its biotechnology and agricultural products. The company earns income by marketing its proprietary products in various regions, particularly in Asia and oth...
CK Life Sciences International (Holdings), Inc. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.49B | 5.52B | 5.32B | 5.28B | 5.40B | 4.94B |
| Gross Profit | 1.69B | 1.69B | 1.64B | 1.63B | 1.63B | 1.41B |
| EBITDA | 9.39M | 337.27M | 624.75M | 469.51M | 449.14M | 353.62M |
| Net Income | -278.39M | -126.55M | 17.25M | 131.96M | 162.80M | 125.23M |
Balance Sheet | ||||||
| Total Assets | 11.29B | 10.79B | 11.25B | 11.27B | 11.73B | 11.98B |
| Cash, Cash Equivalents and Short-Term Investments | 797.84M | 571.21M | 676.16M | 704.13M | 902.47M | 971.71M |
| Total Debt | 6.50B | 6.10B | 5.93B | 5.95B | 6.21B | 6.19B |
| Total Liabilities | 7.63B | 7.28B | 7.06B | 7.11B | 7.23B | 7.26B |
| Stockholders Equity | 3.65B | 3.51B | 4.19B | 4.16B | 4.50B | 4.72B |
Cash Flow | ||||||
| Free Cash Flow | 5.54M | 157.00M | 222.35M | 146.69M | 206.33M | 151.12M |
| Operating Cash Flow | 202.07M | 353.53M | 514.18M | 363.66M | 423.57M | 530.96M |
| Investing Cash Flow | 17.52M | -96.64M | -67.96M | -22.12M | -257.88M | -457.31M |
| Financing Cash Flow | 20.56M | -341.98M | -477.95M | -515.34M | -220.08M | 168.74M |
CK Life Sciences International (Holdings), Inc. Technical Analysis
Neutral
0.83
Price Trends
0.79
Negative
0.82
Negative
0.87
Negative
Market Momentum
-0.03
Negative
51.03
Neutral
93.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0775, the sentiment is Neutral. The current price of 0.83 is above the 20-day moving average (MA) of 0.73, above the 50-day MA of 0.79, and below the 200-day MA of 0.87, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 51.03 is Neutral, neither overbought nor oversold. The STOCH value of 93.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0775.
CK Life Sciences International (Holdings), Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$25.78B | 42.36 | 15.32% | ― | 48.38% | ― | |
54 Neutral | HK$18.61B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$12.67B | 5.89 | 18.28% | ― | 59.70% | 239.97% | |
47 Neutral | HK$6.78B | -34.12 | -4.32% | ― | 74.73% | 32.13% | |
44 Neutral | HK$7.21B | -41.82 | -5.07% | ― | 2.10% | -1350.00% |
* Healthcare Sector Average
HK:0775
CK Life Sciences International (Holdings), Inc.
0.75
0.27
56.25%
HK:1477
Ocumension Therapeutics
8.32
4.07
95.76%
HK:1672
Ascletis Pharma, Inc.
17.54
12.62
256.50%
HK:2142
HBM Holdings Ltd.
14.32
8.34
139.46%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
63.10
50.60
404.80%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
7.50
-0.70
-8.54%
CK Life Sciences International (Holdings), Inc. Corporate Events
CK Life Sciences Subsidiary Reports Encouraging Interim Results for Halneuron® Pain Drug
Dec 23, 2025
CK Life Sciences has reported a positive interim clinical update from its majority-owned subsidiary Dogwood Therapeutics, which is running a Phase 2b trial of Halneuron® for chemotherapy-induced neuropathic pain (CINP). An independent statist...
CK Life Sciences Renews Connected Management Services Deal With Cheung Kong Unit
Dec 19, 2025
CK Life Sciences has renewed its intra‑group service relationship by having its wholly owned subsidiary, RMSPL, enter into a new management agreement with IPL, a wholly owned subsidiary of Cheung Kong Asset (CKA), to provide comprehensive ma...
CK Life Sciences Announces Board Composition and Roles
Nov 3, 2025
CK Life Sciences International (Holdings) Inc. has announced the composition of its board of directors and their roles within the company. The board includes a mix of executive and non-executive directors, with various members serving on committee...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.